PO.MCB05.02 · 分子与细胞生物学

单细胞多组学揭示BRCA1/2高风险输卵管上皮的早期代谢与分化重塑

Early metabolic and differentiation remodeling in BRCA1/2 high-risk fallopian tube epithelium revealed by single-cell multi-omics

海报缩略图:单细胞多组学揭示BRCA1/2高风险输卵管上皮的早期代谢与分化重塑
编号 510 展板 1 时间 4/19 02:00–05:00 区域 Section 21 主讲 Quentin Chartreux, PhD
分会场 Mechanisms and Targets in DNA Damage Repair
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Quentin Chartreux1, Marcela Haro1, Josh Brand2, Andrew Li3, Bobbie J. Rimel4, Patrick Sung5, Simon Gayther1, Huy Dinh2, Fabiola Medeiros3, Kate Lawrenson1

1Center for Inherited Oncogenesis, University of Texas at San Antonio, San Antonio, TX,2School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI,3Cedars-Sinai Medical Center, Los Angeles, CA,4University of Washington, Seattle, WA,5Department of Biochemistry and Structural Biology, University of Texas at San Antonio, San Antonio, TX

摘要 Abstract

中文摘要
BRCA1和BRCA2的胚系突变极大地增加了发生高级别浆液性癌(HGSC)的风险,然而在可能的起源部位——输卵管上皮中驱动恶性转化的最早期分子事件仍然知之甚少。明确这些早期改变对于改善风险预测和为BRCA相关卵巢癌的预防策略提供依据至关重要。为探究高风险个体中最初的细胞和分子扰动,我们对通过脱落细胞学刷检和常规组织标本获得的输卵管伞端样本进行了单细胞转录组和多组学分析。对来自BRCA1/2突变携带者的14份刷检样本、来自平均风险个体的3份刷检样本以及来自平均风险对照的12份组织样本进行了单细胞RNA测序。同时,对来自4名高风险个体和2名平均风险个体的短期上皮培养物进行了单细胞多组学分析,从而对转录状态、染色质可及性和基因调控程序进行整合评估。刷检样本富集了上皮和免疫细胞群,有助于对上皮分化进行高分辨率表征。来自BRCA1/2突变携带者的细胞表现出分泌-纤毛分化轨迹的紊乱,并伴随线粒体呼吸和氧化磷酸化基因的上调,提示高风险上皮中存在早期线粒体和代谢重塑。多组学整合进一步鉴定出一个在BRCA1/2携带者中富集的独特上皮细胞簇,其特征为RUNX3转录因子活性升高。尽管这些细胞在转录上仍与分泌上皮一致,但RUNX3相关程序表明其处于部分或中间分化状态——这可能反映了恶性转化之前的早期谱系不稳定性。还观察到免疫相关通路的微妙改变,提示微环境变化可能有助于形成有利于肿瘤起始的许可性生态位。总之,这些数据揭示了BRCA突变携带者输卵管上皮中早期的转录组、代谢和基因调控重塑。通过界定在肿瘤形成之前被扰动的上皮状态和通路,本研究为遗传性卵巢癌易感性提供了新的机制见解,并突出了用于早期检测和预防的潜在生物标志物。
查看英文原文 English abstract
Germline mutations in BRCA1 and BRCA2 greatly increase the risk of developing high-grade serous carcinoma (HGSC), yet the earliest molecular events driving malignant transformation in the fallopian tube epithelium, the likely site of origin, remain poorly understood. Defining these early alterations is essential for improving risk prediction and informing preventive strategies for BRCA -associated ovarian cancer.To investigate the initial cellular and molecular perturbations in high-risk individuals, we performed single-cell transcriptomic and multi-omic profiling on fallopian tube fimbrial samples obtained through exfoliative cytology brushings and conventional tissue specimens. Single-cell RNA sequencing was conducted on 14 brushings from BRCA1/2 mutation carriers, 3 brushings from average-risk individuals, and 12 tissue samples from average-risk controls. In parallel, single-cell multi-omic analysis was applied to short-term epithelial cultures derived from 4 high-risk and 2 average-risk individuals, enabling an integrated assessment of transcriptional states, chromatin accessibility, and gene regulatory programs.Brushings were enriched for epithelial and immune populations, facilitating high-resolution characterization of epithelial differentiation. Cells from BRCA1/2 mutation carriers exhibited disrupted secretory-ciliated differentiation trajectories, accompanied by upregulation of mitochondrial respiration and oxidative phosphorylation genes, suggesting early mitochondrial and metabolic remodeling in high-risk epithelia. Multi-omic integration further identified a distinct epithelial cluster enriched in BRCA1/2 carriers characterized by increased RUNX3 transcription factor activity. Although these cells remain transcriptionally aligned with secretory epithelium, RUNX3 -associated programs indicate a partial or intermediate differentiation state-potentially reflecting early lineage instability preceding malignant transformation. Subtle alterations in immune-related pathways were also observed, pointing to microenvironmental changes that may support a permissive niche for tumor initiation.Together, these data reveal early transcriptomic, metabolic, and gene-regulatory remodeling in the fallopian tube epithelium of BRCA mutation carriers. By defining epithelial states and pathways perturbed prior to neoplasia, this work provides new mechanistic insight into hereditary ovarian cancer predisposition and highlights potential biomarkers for early detection and prevention.
利益披露 Disclosure
Q. Chartreux, None.. M. Haro, None.. J. Brand, None.. A. Li, None.. B. J. Rimel, None.. P. Sung, None.. S. Gayther, None.. H. Dinh, None.. F. Medeiros, None.. K. Lawrenson, None.

← 返回 AACR 2026 检索